AnaptysBio Q2 net income more than doubles to $177.3 million on 23.5% revenue rise

AnaptysBio posted Q2 net income from continuing operations of USD 177.3 million, versus USD 5.7 million a year earlier. Q2 collaboration revenue rose 23.47% year over year to USD 27.49 million. Cash, cash equivalents and investments totaled USD 164.1 million at June 30, down from USD 211.6 million at Dec. 31, 2025. Management flagged Jemperli global net sales of USD 644 million for the six months ended June 30, up 34% year over year. Updates include a Feb. 2027 FDA PDUFA date for Jemperli in rectal cancer and a Dec. 12, 2026 PDUFA date for Quimilza in GPP.